DermaFlow has developed a non-invasive proprietary and patented technology that accurately and cost effectively measures directly peripheral (in the capillaries) blood flow and detects tell-tale changes in microcirculation. It has been estimated that ~ 90% of disease results in microcirculation changes, and therefore having a "friendly" and affordable way to monitor this routinely is of significant value to modern healthcare. This technology lends itself easily and expediently to three major healthcare trends: *stream-lined 510 K predicate regulatory track designated (for a stand-alone device) * wireless monitoring for home and remote situations * integration into existing monitoring and/or sensing devices DermaFlow has completed early proof-of-concept clinical studies, and is focusing currently on acute care (sepsis in ICU patients) with its first stand alone product Perichek Multi. In addition, Dermaflow has completed development of Perichek - a module suitable for integration into established patient monitoring suites. Dermaflow technology has a wide range of applications in acute and chronic care, both in and out of hospital. We welcome interested corporate, clinical, and strategic partners as well as accredited investors.
View Top Employees from DermaFlowWebsite | http://www.dermaflow.com |
Revenue | $1 million |
Employees | 1 (0 on RocketReach) |
Founded | 2011 |
Address | 316 Monmouth Dr, Cherry Hill, New Jersey 08002, US |
Phone | (856) 479-7410 |
Industry | Medical Equipment Manufacturing, Manufacturing General, Manufacturing |
Competitors | Centric Heart & Vascular, Lexington Foot & Ankle Center, PSC, Palm Bay, Respiratory Therapy schools |
SIC | SIC Code 384 Companies, SIC Code 38 Companies |
NAICS | NAICS Code 33 Companies, NAICS Code 334 Companies |
Looking for a particular DermaFlow employee's phone or email?
The DermaFlow annual revenue was $1 million in 2024.
DermaFlow is based in Cherry Hill, New Jersey.
The NAICS codes for DermaFlow are [33, 334].
The SIC codes for DermaFlow are [384, 38].